Mineralys Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MINERALYS THERAPEUTICS, INC. | |||
| Date: | March 12, 2026 | By: | /s/ Jon Congleton |
|---|---|---|---|
| Jon Congleton | |||
| Chief Executive Officer | |||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Jon Congleton | Chief Executive Officer (Principal Executive Officer) | March 12, 2026 |
| Jon Congleton | ||
| /s/ Adam Levy | Chief Financial Officer and Secretary(Principal Financial and Accounting Officer) | March 12, 2026 |
| Adam Levy | ||
| /s/ Glenn Sblendorio | Chairman | March 12, 2026 |
| Glenn Sblendorio | ||
| /s/ Srinivas Akkaraju | Director | March 12, 2026 |
| Srinivas Akkaraju, M.D., Ph.D. | ||
| /s/ Derek DiRocco | Director | March 12, 2026 |
| Derek DiRocco, Ph.D. | ||
| /s/ Alexander M. Gold | Director | March 12, 2026 |
| Alexander M. Gold, M.D. | ||
| /s/ Daphne Karydas | Director | March 12, 2026 |
| Daphne Karydas | ||
| /s/ Brian Taylor Slingsby | Director | March 12, 2026 |
| Brian Taylor Slingsby, M.D., Ph.D., M.P.H. | ||
– 105 –
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.